LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease

LEQEMBI IQLIK, the lecanemab autoinjector, is now available in the U.S. for initiation of treatment in people with early Alzheimer’s disease. This breakthrough adds a more convenient at-home option to the growing range of Alzheimer’s treatment choices and represents another important step forward in the fight against this devastating disease.